摘要
目的:以药品临床价值为导向,通过综合当前可得的相关证据,开展对阿利沙坦酯治疗原发性高血压的临床综合评价。方法:采用快速评估的方法,基于当前可得证据,围绕阿利沙坦酯治疗原发性高血压的安全性、有效性、经济性、创新性、适宜性和可及性6个维度,开展临床综合评价。结果:安全性方面,阿利沙坦酯的不良事件发生率与氯沙坦钾相当;有效性方面,阿利沙坦酯非劣于氯沙坦钾,并且能在平稳降压的同时保护肾脏靶器官;经济性方面,阿利沙坦酯治疗轻、中度原发性高血压的成本效果优于氯沙坦钾;创新性方面,阿利沙坦酯是我国第一个自主研发的血管紧张素Ⅱ受体阻滞药(ARB),填补了我国在抗高血压创新药物研究和开发领域的空白;适宜性方面,阿利沙坦酯使用方便且便于存储;可及性方面,阿利沙坦酯的价格水平较低、覆盖较广、产能充足、无供应短缺风险。结论:阿利沙坦酯属于国产创新药,其安全性、有效性明确,具有经济性,且在药物技术特性和药品使用方面都具有较好的适宜性。患者可负担性、药品可获得性、可及性均较好。
Objective: To carry out the clinical comprehensive evaluation of allisartan isoproxil in the treatment of essential hypertension guided by the clinical value of drugs and synthesizing the best available evidence. Methods: Using the method of rapid evaluation and based on the currently available evidence, a comprehensive clinical evaluation is carried out around the six dimensions of safety, effectiveness, economy,innovation, suitability and accessibility of allisartan isoproxil in the treatment of essential hypertension.Results: In the terms of safety, the incidence of adverse events of allisartan isoproxil was similar to that of losartan potassium;in terms of effectiveness, allisartan isoproxil is not inferior to losartan potassium,and can protect renal target organs while reducing blood pressure smoothly;in terms of economy, the costeffectiveness of allisartan isoproxil in the treatment of mild and moderate essential hypertension is better than losartan potassium;in terms of innovation, allisartan isoproxil is the first independently developed angiotensin II receptor blocker(ARB) in China, which fills the gap in the research and development of innovative antihypertensive drugs in China;in terms of suitability, allisartan isoproxil is easy to use and store, in terms of accessibility, the price level of allisartan isoproxil is low, the coverage is wide, the production capacity is sufficient, and there is no risk of supply shortage. Conclusion: Allisartan isoproxil is a domestic innovative drug, its safety and effectiveness are clear and it is economical. It has good suitability in drug technical characteristics and drug use. Patients can afford it, and the availability and accessibility of the drug are good.
作者
段承阿鑫
隋宾艳
艾丹丹
许倩
DUAN Cheng-a-xin;SUI Bin-yan;AI Dan-dan;XU Qian(Beijing Health Economics Association,Beijing 100053,China)
出处
《中国合理用药探索》
2022年第3期46-55,共10页
Chinese Journal of Rational Drug Use
关键词
阿利沙坦酯
原发性高血压
临床价值
临床综合评价
多维度评估
allisartan isoproxil
essential hypertension
clinical value
clinical comprehensive evaluation
multi-criteria decision analysis
